← Back to Analyst Consensus 
IRLA Buy
IRulya Therapeutics Inc.
Current Price —
Implied Upside —
Analysts 13
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Next Earnings
Nov 10, 2026 (15 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 9, 2026 | Raymond James | initiate | — → Outperform | — | 54% |
| Sep 24, 2026 | Rodman & Renshaw | initiate | — → Buy | — | 40% |
| Sep 22, 2026 | Citizens | upgrade | Market Perform → Market Outperform | — | 47% |
| Aug 18, 2026 | Cantor Fitzgerald | reiterate | Overweight → Overweight | — | 50% |
| Jul 29, 2026 | Oppenheimer | initiate | Outperform → Outperform | — | 52% |
| Jun 24, 2026 | Leerink Partners | initiate | — → Outperform | — | 51% |
| Jun 23, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
Price Target Trend
Oct 16, 2026 Latest: $75 Oct 25, 2026
EPS Estimates
0q $-1.20
Lo: $-1.40 Hi: $-0.83
3 analysts ▲1
+1y $-4.68
Lo: $-6.60 Hi: $-3.49
3 analysts ▲1
+1q $-1.11
Lo: $-1.60 Hi: $-0.71
3 analysts 0y $-3.65
Lo: $-8.00 Hi: $-0.96
3 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days